Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00404 ...
Drug Name Alprazolam
Molecular Weight 308.765
Molecular Formula C17H13ClN4
CAS Number 28981-97-7
SMILES CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
External Links
DRUGBANK DB00404
T3DB T3D2777
PubChem Compound 2118
PDR 1873
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Melting Point 228.75 ℃ 228-229.5 ℃ Hester, J.B., Jr.; US. Patent3,681,343; August 1,1972; assigned to The Upjohn Company. Hester, J.B., Jr.; US.Patent3,781,289; December 25,1973;assigned to The Upjohn Company. Hester, J.B., Jr.; U S . Patent 3,709898; January 9,1973; assigned t o The Upjohn Company.

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 87.5 % 84-91 % Tablet, PO, oral; DRUGBANK
Bioavailability 88.0 % 88±16 % PO, oral; adults; The Pharmacological Basis of Therapeutics
C Max 17.0 ng/ml 12-22 mcg/L Oral single dose; DRUGBANK
C Max 21.0 ng/ml 21(15-32) ng/ml PO, oral; adults; The Pharmacological Basis of Therapeutics
T Max 1.8 h 1.8 h Tablet, PO, oral; DRUGBANK
T Max 1.5 h 1.5(0.5-3.0) h PO, oral; adults; The Pharmacological Basis of Therapeutics
Clearance 0.0540 L/h/kg 0.90±0.21 ml/min/kg Total clearance; PO, oral; DRUGBANK
Clearance 0.13 L/h/kg 2.13±0.54 ml/min/kg Total clearance; PO, oral; enzyme-inducers; DRUGBANK
Clearance 0.0660 L/h/kg 0.70-1.5 ml/min/kg DRUGBANK
Clearance 0.0444 L/h/kg 0.74±0.14 ml/min/kg hydrolysis; Male, men; Elderly ↓ ;Hepatitis, Hep ↓ ;Obesity ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Clearance 0.0444 L/h/kg 0.74 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1.1 L/kg 0.8-1.3 L/kg PO, oral; DRUGBANK
Volume of Distribution 0.72 L/kg 0.72±0.12 L/kg Elderly → ;Obesity → ;Hepatitis, Hep → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.80 L/kg 0.8 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 11.2 h 11.2 h normal,healthy; patients; Asian ↑ ; DRUGBANK
Half-life 16.3 h 16.3 h Elderly; DRUGBANK
Half-life 35.6 h 5.8-65.3 h alcoholic liver disease; patients; DRUGBANK
Half-life 25.2 h 9.9-40.4 h Obesity; patients; DRUGBANK
Half-life 12.5 h 9-16 h different study; DRUGBANK
Half-life 12.0 h 12±2 h Male, men; Obesity ↑ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 12.0 h 12±2 h RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Half-life 12.0 h 12 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 1251.0 mg/kg 331-2171 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 1020.0 mg/kg 1020.0 mg/kg PO, oral; mouse; T3DB
Eliminate Route 20.0 % 20 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 80.0 % ~80 % DRUGBANK
Protein Binding 71.0 % 71±3 % Elderly → ;Hepatic cirrhosis, cirr ↑ ;Obesity → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 0.06 mg/kg/day 0.06 mg/kg/day PO, oral Xanax alprazolam PDR
Max dose for adolescents 0.06 mg/kg/day 0.06 mg/kg/day PO, oral Xanax alprazolam PDR
Max dose for adults 10.0 mg/day 10 mg/day PO, oral Xanax alprazolam PDR
Max dose for geriatric 10.0 mg/day 10 mg/day PO, oral Xanax alprazolam PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1